Bacillus calmette-guérin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: A randomised prospective study

Massimo Porena, Michele Del Zingaro, Massimo Lazzeri, Luigi Mearini, Antonella Giannantoni, Vittorio Bini, Elisabetta Costantini

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objective: To evaluate the safety, tolerability and efficacy of adjuvant intravesical gemcitabine versus bacillus Calmette-Guérin (BCG) in the treatment of high-risk superficial bladder cancer. Method: 64 patients with high-risk superficial bladder cancer (pT1 and/or G3 and/or CIS) were assigned to interventions (gemcitabine or BCG) in a randomised controlled trial. All the patients were evaluated for recurrence and progression rates (primary endpoint) and safety and tolerability (secondary endpoint). Results: The two groups were comparable in terms of baseline characteristics. Tolerability was better for gemcitabine, whereas the BCG group experienced the need for delayed treatment or withdrawal in 12.5% of cases. At a mean follow-up of 44 months, the recurrence rate in patients treated with BCG was 28.1%; the recurrence rate in patients who received gemcitabine was 53.1% (p = 0.037). Time to recurrence was shorter in patients treated with BCG (25.6 vs. 39.4 months, p = 0.042). No patients developed disease progression. Conclusions: Gemcitabine is significantly inferior to BCG, but given its favourable toxicity profile, it may be useful for patients intolerant to or otherwise unable to receive BCG.

Original languageEnglish
Pages (from-to)23-27
Number of pages5
JournalUrologia Internationalis
Volume84
Issue number1
DOIs
Publication statusPublished - Feb 2010

Fingerprint

gemcitabine
Urinary Bladder Neoplasms
Bacillus
Prospective Studies
Recurrence
Therapeutics
Safety
Disease Progression
Randomized Controlled Trials

Keywords

  • Bacillus Calmette-Guérin
  • Gemcitabine
  • Superficial bladder cancer, therapy

ASJC Scopus subject areas

  • Urology

Cite this

Bacillus calmette-guérin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer : A randomised prospective study. / Porena, Massimo; Del Zingaro, Michele; Lazzeri, Massimo; Mearini, Luigi; Giannantoni, Antonella; Bini, Vittorio; Costantini, Elisabetta.

In: Urologia Internationalis, Vol. 84, No. 1, 02.2010, p. 23-27.

Research output: Contribution to journalArticle

Porena, Massimo ; Del Zingaro, Michele ; Lazzeri, Massimo ; Mearini, Luigi ; Giannantoni, Antonella ; Bini, Vittorio ; Costantini, Elisabetta. / Bacillus calmette-guérin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer : A randomised prospective study. In: Urologia Internationalis. 2010 ; Vol. 84, No. 1. pp. 23-27.
@article{27436582b0f045cdaca1ca013e772b08,
title = "Bacillus calmette-gu{\'e}rin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: A randomised prospective study",
abstract = "Objective: To evaluate the safety, tolerability and efficacy of adjuvant intravesical gemcitabine versus bacillus Calmette-Gu{\'e}rin (BCG) in the treatment of high-risk superficial bladder cancer. Method: 64 patients with high-risk superficial bladder cancer (pT1 and/or G3 and/or CIS) were assigned to interventions (gemcitabine or BCG) in a randomised controlled trial. All the patients were evaluated for recurrence and progression rates (primary endpoint) and safety and tolerability (secondary endpoint). Results: The two groups were comparable in terms of baseline characteristics. Tolerability was better for gemcitabine, whereas the BCG group experienced the need for delayed treatment or withdrawal in 12.5{\%} of cases. At a mean follow-up of 44 months, the recurrence rate in patients treated with BCG was 28.1{\%}; the recurrence rate in patients who received gemcitabine was 53.1{\%} (p = 0.037). Time to recurrence was shorter in patients treated with BCG (25.6 vs. 39.4 months, p = 0.042). No patients developed disease progression. Conclusions: Gemcitabine is significantly inferior to BCG, but given its favourable toxicity profile, it may be useful for patients intolerant to or otherwise unable to receive BCG.",
keywords = "Bacillus Calmette-Gu{\'e}rin, Gemcitabine, Superficial bladder cancer, therapy",
author = "Massimo Porena and {Del Zingaro}, Michele and Massimo Lazzeri and Luigi Mearini and Antonella Giannantoni and Vittorio Bini and Elisabetta Costantini",
year = "2010",
month = "2",
doi = "10.1159/000273461",
language = "English",
volume = "84",
pages = "23--27",
journal = "Urologia Internationalis",
issn = "0042-1138",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Bacillus calmette-guérin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer

T2 - A randomised prospective study

AU - Porena, Massimo

AU - Del Zingaro, Michele

AU - Lazzeri, Massimo

AU - Mearini, Luigi

AU - Giannantoni, Antonella

AU - Bini, Vittorio

AU - Costantini, Elisabetta

PY - 2010/2

Y1 - 2010/2

N2 - Objective: To evaluate the safety, tolerability and efficacy of adjuvant intravesical gemcitabine versus bacillus Calmette-Guérin (BCG) in the treatment of high-risk superficial bladder cancer. Method: 64 patients with high-risk superficial bladder cancer (pT1 and/or G3 and/or CIS) were assigned to interventions (gemcitabine or BCG) in a randomised controlled trial. All the patients were evaluated for recurrence and progression rates (primary endpoint) and safety and tolerability (secondary endpoint). Results: The two groups were comparable in terms of baseline characteristics. Tolerability was better for gemcitabine, whereas the BCG group experienced the need for delayed treatment or withdrawal in 12.5% of cases. At a mean follow-up of 44 months, the recurrence rate in patients treated with BCG was 28.1%; the recurrence rate in patients who received gemcitabine was 53.1% (p = 0.037). Time to recurrence was shorter in patients treated with BCG (25.6 vs. 39.4 months, p = 0.042). No patients developed disease progression. Conclusions: Gemcitabine is significantly inferior to BCG, but given its favourable toxicity profile, it may be useful for patients intolerant to or otherwise unable to receive BCG.

AB - Objective: To evaluate the safety, tolerability and efficacy of adjuvant intravesical gemcitabine versus bacillus Calmette-Guérin (BCG) in the treatment of high-risk superficial bladder cancer. Method: 64 patients with high-risk superficial bladder cancer (pT1 and/or G3 and/or CIS) were assigned to interventions (gemcitabine or BCG) in a randomised controlled trial. All the patients were evaluated for recurrence and progression rates (primary endpoint) and safety and tolerability (secondary endpoint). Results: The two groups were comparable in terms of baseline characteristics. Tolerability was better for gemcitabine, whereas the BCG group experienced the need for delayed treatment or withdrawal in 12.5% of cases. At a mean follow-up of 44 months, the recurrence rate in patients treated with BCG was 28.1%; the recurrence rate in patients who received gemcitabine was 53.1% (p = 0.037). Time to recurrence was shorter in patients treated with BCG (25.6 vs. 39.4 months, p = 0.042). No patients developed disease progression. Conclusions: Gemcitabine is significantly inferior to BCG, but given its favourable toxicity profile, it may be useful for patients intolerant to or otherwise unable to receive BCG.

KW - Bacillus Calmette-Guérin

KW - Gemcitabine

KW - Superficial bladder cancer, therapy

UR - http://www.scopus.com/inward/record.url?scp=77649131471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649131471&partnerID=8YFLogxK

U2 - 10.1159/000273461

DO - 10.1159/000273461

M3 - Article

C2 - 20173364

AN - SCOPUS:77649131471

VL - 84

SP - 23

EP - 27

JO - Urologia Internationalis

JF - Urologia Internationalis

SN - 0042-1138

IS - 1

ER -